Apple and Novartis: Strong Performance Amid Challenges
Apple (NASDAQ: AAPL) reported a 10% year-over-year increase in third-quarter sales, reaching $94 billion, with earnings per share growing 12% to $1.57. The company has secured a deal with President Trump to invest $600 billion in U.S. manufacturing, which mitigates tariff impacts from aggressive trade policies. Apple generated $96.2 billion in free cash flow over the past year, despite an 11.6% decline from the previous period. As of now, Apple maintains a modest dividend payout ratio of 14%.
Novartis (NYSE: NVS) posted a 12% increase in second-quarter net sales, totaling $14.1 billion, while net income rose 24% to $4 billion. The pharmaceutical giant anticipates high single-digit top-line growth for the year, even as it prepares for competition from generics for its popular drug, Entresto. Currently, seven of Novartis’ products are generating over $1 billion in annual sales, showcasing its strong, diversified portfolio and ongoing commitment to innovation in drug development.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
